Standard BioTools Inc. Capital Expenditures Incurred but Not yet Paid
Standard BioTools Inc. (LAB) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-05
- Standard BioTools Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$319.00K.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $319.00K, a 71.89% decline year-over-year.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $716.00K, a 18.54% decline year-over-year.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$48.00K, a 105.13% decline year-over-year.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $851.00K, a 53.09% decline from fiscal 2024.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $1.81M.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Standard BioTools Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $3.83M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month | Capital Expenditures Incurred but Not yet Paid 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $716.00K derived: sum of 3 quarters · filed 2026-08-05 | $668.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $319.00K 10-Q · filed 2026-05-06 | $1.03M derived: sum of 2 quarters · filed 2026-05-06 | $987.00K derived: sum of 3 quarters · filed 2026-05-06 | $35.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $716.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $668.00K derived: sum of 2 quarters · filed 2026-03-16 | -$284.00K derived: sum of 3 quarters · filed 2026-08-05 | $851.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.00M derived: sum of 2 quarters · filed 2026-08-05 | $135.00K 10-Q · filed 2025-11-04 | $1.01M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$952.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $183.00K 10-Q · filed 2026-08-05 | $1.06M derived: sum of 3 quarters · filed 2026-08-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $1.14M 10-Q · filed 2026-05-06 | $2.01M derived: sum of 2 quarters · filed 2026-05-06 | $2.95M derived: sum of 3 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $879.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.81M derived: sum of 2 quarters · filed 2026-03-16 | $1.81M 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $935.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $935.00K 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-15 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-03-16 | $2.83M 10-K · filed 2025-03-11 | |||
| 2022-12-31 | $3.83M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |